{"organizations": [], "uuid": "9f8c82931c58a60c21e1857b12486ed2e89cd89d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/02/20/the-associated-press-ultragenyx-reports-4q-loss.html", "country": "US", "domain_rank": 767, "title": "Ultragenyx reports 4Q loss", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-21T00:17:00.000+02:00", "replies_count": 0, "uuid": "9f8c82931c58a60c21e1857b12486ed2e89cd89d"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/02/20/the-associated-press-ultragenyx-reports-4q-loss.html", "ord_in_thread": 0, "title": "Ultragenyx reports 4Q loss", "locations": [], "entities": {"persons": [{"name": "ultragenyx", "sentiment": "negative"}], "locations": [{"name": "novato", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "novato", "sentiment": "none"}], "organizations": [{"name": "ultragenyx pharmaceutical inc.", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Tuesday reported a loss of $81.7 million in its fourth quarter.\nOn a per-share basis, the Novato, California-based company said it had a loss of $1.89. Losses, adjusted for pretax gains, came to $2.27 per share.\nThe results fell short of Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of $2 per share.\nThe biotechnology company posted revenue of $2.4 million in the period.\nFor the year, the company reported that its loss widened to $302.1 million, or $7.12 per share. Revenue was reported as $2.6 million.\nUltragenyx shares have risen roughly 4 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $48.18, a fall of 37 percent in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE", "external_links": [], "published": "2018-02-21T00:17:00.000+02:00", "crawled": "2018-02-21T01:28:06.017+02:00", "highlightTitle": ""}